In this randomized clinical trial, an NT-proBNP–guided strategy to identify and treat patients at elevated risk with neurohormonal therapy was feasible, safe, and did not result in worsening of PROs among patients with breast cancer or lymphoma undergoing anthracycline chemotherapy. This evidence concerns the gene NPPB and lymphoma.